Public on NASDAQ on Mar, 2019 Public on TASE on Mar, 2019 Public on TASE on Jul, 2019 Public on TASE on Feb, 2021
?
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Enlivex Therapeutics R&D
Enlivex Therapeutics R&D Overview
Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming. The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications.
The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials.
In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.